反应详情

Reaction of (E)-N-(4-(3-bromophenylamino)quinazolin-6-yl)-4-(piperidin-1-yl)but-2-enamide (12) (1.0 g, 2.14 mmol) in NMP (4 mL) with 5-(bromomethyl)-1-methyl-4-nitro-1H-imidazole (105) (315 mg, 1.43 mmol) for 3.5 days, according to general procedure D gave 1-((2E)-4-{[4-(3-bromoanilino)-6-quinazolinyl]amino}-4-oxo-2-butenyl)-1-[(1-methyl-4-nitro-1H-imidazol-5-yl)methyl]piperidinium bromide (23) (600 mg, 61%), m.p. 188° C. (dec.). 1H NMR [(CD3)2SO] δ 10.73 (s, 1H), 9.94 (s, 1H), 8.82 (s, 1H), 8.61 (s, 1H), 8.17 (t, J=1.8 Hz, 1H), 8.14 (s, 1H), 7.98 (d, J=8.8 Hz, 1H), 7.88-7.83 (m, 2H), 7.37-7.29 (m, 2H), 7.08 (td, J=7.3, 15.1 Hz, 1H), 6.80 (d, J=15.1 Hz, 1H), 5.02 (br s, 2H), 4.62 (br s, 2H), 3.87 (s, 3H), 3.58-3.55 (m, 2H), 2.04-1.99 (m, 2H), 1.78-1.75 (m, 2H), 1.64-1.61 (m, 1H), 1.46-1.36 (m, 1H). Analysis found: C, 48.24; H, 4.58; N, 15.89. C28H30Br2N8O3.½H2O requires: C, 48.36; H, 4.49; N, 16.11. HRMS (FAB+) found: 605.16226, 607.15997 (M-Br), calcd. for C28H3079/81BrN8O3+: 605.16242, 607.16038.